Literature DB >> 19473864

The International Olympic Committee (IOC) and GH-2000.

Peter Sönksen1.   

Abstract

The IOC recognised growth hormone (GH) as a drug of abuse in 1992 and recruited me as an expert to advise them on the development of a test to detect its abuse. After a long gestation period where the IOC gradually changed their attitude to research they co-funded the GH-2000 project with the European Union (EU). GH-2000 was a unique consortium of Europe's best endocrinologists and scientists in partnership with two GH manufacturers and the IOC with a greater than two million dollar budget. GH-2000 selected a method based on the measurement of GH-dependent markers and selected IGF-I and P-III-P as the most suitable markers and demonstrated that they could detect 100% of men taking GH with a false-positive rate better than 1:10,000; sensitivity was reduced however in women. GH-2000 reported back to EU and IOC in January 1999 in time to have the test available for the 2000 Olympic Games. Results were quality assured by an expert workshop. Politics has prevented this from happening however, some reasons are discussed as to why 9 years later it still has not been introduced.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19473864     DOI: 10.1016/j.ghir.2009.04.015

Source DB:  PubMed          Journal:  Growth Horm IGF Res        ISSN: 1096-6374            Impact factor:   2.372


  3 in total

Review 1.  Detecting growth hormone misuse in athletes.

Authors:  Richard I G Holt
Journal:  Indian J Endocrinol Metab       Date:  2013-10

Review 2.  Insulin-Like Growth Factor-1 (IGF-1) and Its Monitoring in Medical Diagnostic and in Sports.

Authors:  Julian Bailes; Mikhail Soloviev
Journal:  Biomolecules       Date:  2021-02-04

3.  Plasma biomarker proteins for detection of human growth hormone administration in athletes.

Authors:  Sock-Hwee Tan; Albert Lee; Dana Pascovici; Natasha Care; Vita Birzniece; Ken Ho; Mark P Molloy; Alamgir Khan
Journal:  Sci Rep       Date:  2017-08-30       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.